BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smolewski P, Rydygier D. Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders. Expert Opinion on Investigational Drugs 2019;28:421-33. [DOI: 10.1080/13543784.2019.1596258] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Tundo GR, Sbardella D, Santoro AM, Coletta A, Oddone F, Grasso G, Milardi D, Lacal PM, Marini S, Purrello R, Graziani G, Coletta M. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. Pharmacol Ther 2020;213:107579. [PMID: 32442437 DOI: 10.1016/j.pharmthera.2020.107579] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
2 Xie SC, Dick LR, Gould A, Brand S, Tilley L. The proteasome as a target for protozoan parasites. Expert Opin Ther Targets 2019;23:903-14. [PMID: 31679410 DOI: 10.1080/14728222.2019.1685981] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
3 Roeten MSF, van Meerloo J, Kwidama ZJ, Ter Huizen G, Segerink WH, Zweegman S, Kaspers GJL, Jansen G, Cloos J. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells. Cells 2021;10:665. [PMID: 33802801 DOI: 10.3390/cells10030665] [Reference Citation Analysis]
4 Li W, Wen W, Chen S, Ding L, He B, Zhang Y, Li B, Zhu L. Copper(II)-Catalyzed 1,6-Hydroboration Reactions of p‑Quinone Methides Under Ligand-Free Conditions: A Sequential Methodology to gem-Disubstituted Methanols. Catal Lett. [DOI: 10.1007/s10562-022-04063-7] [Reference Citation Analysis]
5 Sokol J, Guman T, Chudej J, Hlebaskova M, Stecova N, Valekova L, Kucerikova M, Stasko J. Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma. Ann Hematol 2021. [PMID: 34550463 DOI: 10.1007/s00277-021-04663-0] [Reference Citation Analysis]